The role of apoptosis in autoantibody production

Reumatismo

Volumn 59, Issue 2, 2007, Pages 87-99

  Herrera Esparza, Rafael ^a,b   Herrera van Oostdam, D ^a   Lopez Robles E ^a   Avalos Diaz E ^a  

^a UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

^b NONE   (Mexico)

Author keywords

Apoptosis; Autoantibodies; Autoimmunity; Caspases; Fas FasL

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTINUCLEAR ANTIBODY; ANTITHYROID AGENT; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CASPASE; CHLOROTHIAZIDE; CHLORPROMAZINE; DEATH RECEPTOR; DIURETIC AGENT; EPITOPE; FAS LIGAND; HYDRALAZINE; ISONIAZID; MERCURY; METHYLDOPA; PENICILLAMINE; PHENYTOIN; PROCAINAMIDE; PROPYLTHIOURACIL; QUINIDINE; SALAZOSULFAPYRIDINE; TERBINAFINE; THIAMAZOLE; VALPROIC ACID;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BULLOUS SKIN DISEASE; DNA METHYLATION; EDITORIAL; GENE REARRANGEMENT; HEAVY METAL POISONING; HUMAN; MITOCHONDRION; MOLECULAR MIMICRY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TOXIC HEPATITIS; VASCULITIS; BIOSYNTHESIS; IMMUNOLOGY;

APOPTOSIS; AUTOANTIBODIES; HUMANS;

EID: 35448988088     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (152)

1. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 317-30.
2. Wardemann H, Yurasov S; Schaefer A; Young JW, Meffre E, Nussenzweig, MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301: 1374-7.
3. Kompfner E, Oliveira, P, Montalbano A, Feeney AJ. Unusual germline DSP2 gene accounts for all apparent V-D-D-J rearrangements in newborn, but not adult, MRL mice. J Immunol 2001; 167: 6933-8.
4. Kleinstein S, Louzoun Y, Shlomchik MJ. Estimating hypermutation rates from clonal tree data. J Immunol 2003; 171: 639-49.
5. Diamond B, Scharff MD. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci USA 1984; 81: 5841-44.
6. Fraser NLW, Rowley G, Field M, Stott DI. The VH gene repertoire of splenic B cells and somatic hypermutation in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: R114-21.
7. Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol Immunol 2004; 40: 1113-20.
8. Arbuckle MR, Reichlin M, Harley JB, James JA. Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand J Immunol 1999; 50: 447-55.
9. Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med 2003; 197: 1501-10.
10. Ménard HA, Lapointe E, Rochdi MD, Zhou Z. Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000; 2: 429-32.
11. Vossenaar ER, Despres N, Lapointe E, Van Der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004: 6: R142-50.
12. Oldstone MBA. Molecular mimicry and immune-mediated diseases. FASEB J 1998; 12: 1255-65.
13. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9: 914-20.
14. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797-804.
15. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62: 388-93.
16. Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol 2004; 172: 661-8.
17. Rose NR. Autoimmune disease 2002: an overview. J Invest Dermatol Symp Proc 2004; 9: 1-4.
18. Lernmark Å. Autoimmune diseases: are markers ready for prediction? J Clin Invest 2001; 108; 1091-6.
19. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001; 108: 1417-22.
20. Fritzler MJ. Autoantibodies: diagnostic fingerprints and etiologic perplexities. Clin Invest Med 1997; 20: 50-66.
21. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-43.
22. Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 2000; 5: 443-9.
23. Qian Y, Wang H, Clarke SH. Impaired clearance of apoptotic cells induces the activation of autoreactive anti-Sm marginal zone and B-1 B cells. J Immunol 2004; 172: 625-35.
24. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15: 185-93.
25. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361-70.
26. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019-23.
27. Oehm, A, Behrmann, I, Falk W, Pawlita, M, Maier, G, Klas, C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992; 267: 10709-15.
28. Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol 2003; 23: 317-32.
29. Shakibaei M, Schulze-Tanzil G, Takada Y, Aggarwal BB. Redox regulation of apoptosis by members of the TNF superfamily. Antioxid Redox Signal 2005; 7: 482-96.
30. Sheikh MS, Huang Y. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 2004; 4: 97-104.
31. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932-7.
32. Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 2002; 16: 742-4.
33. Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci 2005; 118: 265-7.
34. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817-29.
35. Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 1991; 147: 3165-9.
36. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem 2000; 275: 40974-80.
37. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
38. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-73.
39. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-87.
40. Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci 2003; 116: 4053-6.
41. Micheau O, Tschopp J. Induction of TNF receptor Imediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-90.
42. French LE, Tschopp J. Protein-based therapeutic approaches targeting death receptors. Cell Death Differ 2003; 10: 117-23.
43. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 2005; 280: 14507-13.
44. Degli Esposti M. Mitochondria in apoptosis: past, present and future. Biochem Soc Trans 2004; 32: 493-5.
45. Nicholson DW, Thornberry NA. Apoptosis. Life and death decisions. Science 2003; 299: 214-5.
46. Jiang X, Kim HE; Shu H, Zhao Y, Zhang H, Kofron J, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 2003; 299: 223-6.
47. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell 2004; 14: 277-87.
48. Savill J, Gregory C, Haslett C. Cell biology. Eat me or die. Science 2003; 302: 1516-7.
49. Sohon SJ, Rajpal A, Winoto A. Apoptosis during lymphoid development. Curr Opin Immunol 2003; 15: 209-16.
50. Sprent J, Kishimoto H. The thymus and negative selection. Immunol Rev 2002; 185: 126-35.
51. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-4.
52. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-710.
53. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967; 70: 891-9.
54. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-55.
55. Nagata S, Suda T. Fas and Fas ligand: 1pr and gld mutations. Immunol Today 1995; 16: 39-43.
56. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts I, Debatin K, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-9.
57. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 2003; 10: 124-33.
58. Di Cristofano A, Kosti P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999; 285: 2122-5.
59. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J.Clin Invest 1999; 103: 355-63.
60. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, Davis MM, et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 1995; 376: 181-4.
61. Singer GG, Abbas A K. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1: 365-71.
62. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-8.
63. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulationinduced apoptosis and deletion of autoreactive B cells. J Exp Med 2003; 198: 1119-26.
64. Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol 2001; 167: 5963-9.
65. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000; 192: 359-66.
66. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76: 227-324.
67. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56-9.
68. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997; 158: 4525-8.
69. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998; 188: 2313-20.
70. Boackle SA, Holers VM. Role of complement in the development of autoimmunity. Curr Dir Autoimmun 2003; 6: 154-68.
71. Nauta AJ, Raaschou-Jensen N, Roos A, Daha MR, Madsen HO, Borrias-Essers MC, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003; 33: 2853-63.
72. Stuart L.M, Takahashi K, Shi L, Savill J, Ezekowitz RAB. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J Immunol 2005; 174: 3220-6.
73. Werth VP, Berlin J.A, Callen JP, Mick R, Sullivan KE. Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. J Invest Dermatol 2002; 119: 1394-9.
74. Widlak P, Garrard WT. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 2005; 94: 1078-87.
75. Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFNalpha inducer. J Immunol 2000; 165: 3519-26.
76. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174: 2499-506.
77. Cabrespines A, Laderach D, Lebosse C, Bach J, Koutouzov S. Isolation and characterization of apoptotic nucleosomes, free and complexed with lupus autoantibody generated during hybridoma B-cell apoptosis. J Autoimmun 1998; 11: 19-27.
78. Huck S, Deveaud E, Namane A, Zouali M. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis FASEB J 1999; 13: 1415-22.
79. Decker P, Singh-Jasuja H, Haager S, Kötter I, Rammense HG. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol 2005; 174: 3326-34.
80. Hernandez-Verdun D, Roussel P. Regulators of nucleolar functions. Prog Cell Cycle Res 2003; 5: 301-8.
81. Leung AK, Andersen JS, Mann M, Lamond AI. Bioinformatic analysis of the nucleolus. Biochem J 2003; 376: 553-69.
82. Biggiogera M, Bottone MG, Scovassi AI, Soldani C, Vecchio L, Pellicciari C. Rearrangement of nuclear ribonucleoprotein (RNP)-containing structures during apoptosis and transcriptional arrest. Biol Cell 2004; 96: 603-15.
83. Wilson KS, Noller HF. Molecular movement inside the translational engine. Cell 1998; 92: 337-49.
84. Nadano D, Sato TA. Caspase-3-dependent and -independent degradation of 28 S ribosomal RNA may be involved in the inhibition of protein synthesis during apoptosis initiated by death receptor engagement. J Biol Chem 2000; 275: 13967-73.
85. Degen WGJ, Pruijn GJM, Raats JMH, van Venrooij WJ. Caspase-dependent cleavage of nucleic acids. Cell Death Differ 2000; 7: 616-27.
86. Lührmann RM, Kastner B, Bach M. Structure of spliceosomal snRNPs and their role in pre-mRNA splicing. Biochim Biophys Acta 1990; 1087: 265-92.
87. Casciola-Rosen LA, Miller DK, Anhalt GJ, Rosen A. Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem 1994; 269: 30757-60.
88. Malmegrim KCR, Pruijn GJM, van Venrooij WJ. The fate of the U1 snRNP autoantigen during apoptosis: implications for systemic autoimmunity. Isr Med Assoc J (IMAJ) 2002; 4: 706-12.
89. Hof D, Cheung K, de Rooij DJ, van den Hoogen FH, Pruijn, GJ, van Venrooij WJ, et al. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res Ther 2005; 7: R302-9.
90. Ramirez-Sandoval R, Sanchez-Rodriguez SH, Herrera-van Oostdam D, Avalos-Diaz E, Herrera-Esparza R. Antinuclear antibodies recognize cellular autoantigens driven by apoptosis. Joint Bone Spine 2003; 70: 187-94.
91. Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity Arthritis Rheum 2001; 44: 2642-52.
92. Degen WG, Aarssen Y, Pruijn GJ, Utz PJ, van Venrooij WJ. The fate of U1 snRNP during anti-Fas induced apoptosis: specific cleavage of the U1 snRNA molecule. Cell Death Differ 2000; 7: 70-9.
93. Allemand E, Guil S, Myers M, Moscat J, Caceres JF, Krainer AR. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci. USA 2005; 102: 3605-10.
94. Brockstedt E, Rickers A, Kostka S, Laubersheimer A, Dorken B, Wittmann-Liebold B, et al. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J Biol Chem 1998; 237: 28057-64.
95. Thiede B, Dimmler C, Siejak F, Rudel T. Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis. J Biol Chem 2001; 276: 26044-50.
96. Rutjes SA, van der Heijden A, Utz PJ, van Venrooij WJ, Pruijn GJ. Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis. J Biol Chem 1999; 274: 24799-807.
97. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996; 184: 765-70.
98. Casciola-Rosen LA, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation 33 of autoimmunity. J Exp Med 1999; 190: 815-26.
99. Ayukawa K, Taniguchi S, Masumoto J, Hashimoto S, Sarvotham H, Hara A, et al. La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis. J Bio Chem 2000; 275: 34465-70.
100. Rosen A, Casciola-Rosen LA. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
101. Casciola-Rosen LA, Anhalt GJ, Rosen A. DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 1995; 182: 1625-34.
102. Talanian RV, Yang XH, Turbov J, Seth P, Ghayur T, Casiano CA, et al. Granule-mediated killing: pathways for granzyme B-initiated apoptosis. J Exp Med 1997; 186: 1323-31.
103. Bokoch GM. Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction? Cell Death Differ 1998; 5: 637-45.
104. Kamachi M, Le TM, Kim S.J, Geiger ME, Anderson P, Utz PJ. Human autoimmune sera as molecular probes for the identification of an autoantigen kinase signaling pathway. J Exp Med 2002; 196: 1213-25.
105. Neugebauer KM, Merrill JT, Wener MH, Lahita RG, Roth MB. SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. Arthr Rheum 2000; 43: 1768-78.
106. Overzet K, Gensler TJ, Kim SJ, Geiger ME, van Venrooij WJ, Pollard KM, et al. Small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during apoptosis. Arthritis Rheum 2000; 43: 1327-36.
107. Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997; 185: 843-54.
108. Fritzler MJ, Hamel JC, Ochs RL, Chan EKL. Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex. J Exp Med 1993; 178: 49-62.
109. Fritzler MJ, Lung CC, Hamel JC, Griffith K, Chan EKL. Molecular characterization of Golgin-245, a novel Golgi complex protein containing a granin signature. J Biol Chem 1995; 270: 31262-8.
110. Nozawa K, Fritzler MJ, von Muhlen CA, Chan EK. Giantin is the major Golgi autoantigen in human anti-Golgi complex sera. Arthritis Res Ther 2004; 6: R95-102.
111. Cha H, Smith BL, Gallo K, Machamer CE, Shapiro P. Phosphorylation of golgin-160 by mixed lineage kinase 3. J Cell Sci 2004; 117: 751-60.
112. Rutjes SA, Utz PJ, van der Heijden A, Broekhuis C, van Venrooij WJ, Pruijn GJ. The La (SS-B) autoantigen, a key protein in RNA biogenesis, is dephosphorylated and cleaved early during apoptosis. Cell Death Differ 1999; 6: 976-86.
113. Utz PJ, Gensler TJ, Anderson P. Death, autoantigen modifications, and tolerance. Arthritis Res 2000; 2: 101-14.
114. Zampieri S, Degen W, Ghiradello A, Doria A, van Venrooij WJ. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 72-6.
115. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005; 4: 309-14.
116. Atzeni F, Marrazza MG, Sarzi-Puttini P, Carrabba M, Atzeni F. Drug-induced lupus erythematosus. Reumatismo 2003; 55: 147-54.
117. Alarcon-Segovia D, Wakim KG, Worthington JW, Ward LE. Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine (Baltimore) 1967; 46: 1-33.
118. Ablin J, Verbovetski I, Trahtemberg U, Metzger S, Mevorach D. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus. Apoptosis 2005; 10: 1009-18.
119. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005; 174: 6212-9.
120. Alarcon-Segovia D, Fishbein E. Patterns of antinuclear antibodies and lupus-activating drugs. J Rheumatol 1975; 2: 167-71.
121. Vazquez-Del-Mercado M, Casiano CA, Rubin RL. IgA antihistone antibodies in isoniazid-treated tuberculosis patients. Autoimmunity 1995; 20: 105-11.
122. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997; 34: 758-60.
123. Nordstrom DM, West SG, Rubin RL. Methyldopa-induced systemic lupus erythematosus. Arthritis Rheum 1989; 32: 205-8.
124. Homberg JC. Drug-induced autoimmune hemolytic anemia. Presse Med 1999; 28: 703-8.
125. Richardson B, Ray D, Yung R. Murine models of lupus induced by hypomethylated T cells. Methods Mol Med 2004; 102: 285-94.
126. Baeza I, Leyva E, Campos B, Lara M, Ibanez M, Farfan N, et al. Antibodies to non-bilayer phospholipid arrangements induce a murine autoimmune disease resembling human lupus. Eur J Immunol 2004; 34: 576-86.
127. Hieronymus T, Grotsch P, Blank N, Grunke M, Capraru D, Geiler T, et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 2000; 43: 1994-2004.
128. Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum 2000; 43: 420-8.
129. Gunnarsson I, Nordmark B, Hassan-Bakri A, Grondal G, Larsson P, Forslid J, et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford) 2000; 39: 886-93.
130. Furet Y, Bechtel Y, Le Guellec C, Bechtel PR, Autret-Leca E, Paintaud G. Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. Therapie 2002; 57: 427-31.
131. Jain KK. Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Saf 1991; 6: 350-60.
132. Furst SM, Uetrecht JP. The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro. Int J Immunopharmacol 1995; 17: 445-52.
133. Mizutani T, Shinoda M, Tanaka Y, Kuno T, Hattori A, Usui T, et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev 2005; 37: 235-52.
134. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf 2004; 3: 655-65.
135. Villasenor-Garcia MM, Puebla-Perez AM, Sandoval-Ramirez L, Lozoya X. Phenytoin and electric shockinduced apoptosis in rat peripheral blood lymphocytes. Int J Immunopharmacol 2000; 22: 143-50.
136. Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. J Clin Pharmacol 2002; 42: 247-66.
137. Wiik A. Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 2005; 7: 191-2.
138. Tamura M, Kimura H, Koji T, Tominaga T, Ashizawa K, Kiriyama T, et al. Role of apoptosis of thyrocytes in a rat model of goiter. A possible involvement of Fas system. Endocrinology 1998; 139: 3646-53.
139. Seguin B, Boutros PC, Li X, Okey AB, Uetrecht JP. Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger. Chem Res Toxicol 2005; 18: 1193-202.
140. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-9.
141. Querin S, Feuillet-Fieux MN, Jacob L, Niel G, Bach JF. Specificity of acebutolol-induced antinuclear antibodies. J Immunopharmacol 1986; 8: 633-49.
142. Wilson JD. Antinuclear antibodies and cardiovascular drugs. Drugs 1980; 19: 292-305.
143. Bonnet, F, Morlat, P, de Witte, S, Combe. C, Beylot, J Lupus-like syndrome and vasculitis induced by valpromide. J Rheumatol 2003; 30: 208-9.
144. Asconape JJ, Manning KR, Lancman ME. Systemic lupus erythematosus associated with use of valproate. Epilepsia 1994; 35: 162-3.
145. McKay DA, Schofield OM, Benton EC. Terbinafine induced subacute cutaneous lupus erythematosus. Acta Derm Venereol 2004; 84: 472-4.
146. Bonsmann G, Schiller M, Luger TA, Stander S. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001; 44: 925-31.
147. Arnett FC, Fritzler MJ, Ahn C, Holian A. Urinary mercury levels in patients with autoantibodies to U3-RNP (fibrillarin). J Rheumatol 2000; 27: 405-10.
148. Pacheco FJ, Servin J, Dang D, Kim J, Molinaro C, Daniels T, et al. Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death. Arthritis Rheum 2005; 52: 2133-5.
149. Herrera-vanOostdam DA, Esparza-Ibarra E, Ramirez-Sandoval R, Ortiz V, Bollain-y-Goitia JJ, Avalos-Diaz E, et al. Apoptosis and necrosis increase antigenicity of proteins recognized by antinuclear antibodies. Reumatismo 2004; 56: 156-61.
150. Herrera-Esparza R, Villalobos R, Bollain-Y-Goytia JJ, Ramirez-Sandoval R, Sanchez-Rodriguez SH, Pacheco-Tovar G, et al. Apoptosis and redistribution of the Ro autoantigen in Balb/c mouse like in subacute cutaneous lupus erythematosus. Clin Dev Immunol. 2006;13:163-6.
151. Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, et al. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 1998; 4: 545-57.
152. Ayukawa K, Taniguchi S, Masumoto J, Hashimoto S, Sarvotham H, Hara A, et al. La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis. J Biol Chem 2000; 275: 34465-70.